Anticancer activity of tetracationic arene ruthenium metalla-cycles

A series of cationic metalla-cycles of the general formulae [(η(6)-p-cym)(4)Ru(4)(OO∩OO)(2)(N∩N)(2)](4+) and [(η(6)-p-cym)(4)Ru(4)(NO∩NO)(2)(N∩N)(2)](4+) has been prepared from the dinuclear arene ruthenium precursors [(η(6)-p-cym)(2)Ru(2)(OO∩OO)(2)Cl(2)] (OO∩OO = oxalato, 1,4-benzoquinonato-2,5-dio...

Full description

Saved in:
Bibliographic Details
Published in:Dalton transactions : an international journal of inorganic chemistry 2011-07, Vol.40 (27), p.7172-7180
Main Authors: Barry, Nicolas P E, Edafe, Fabio, Therrien, Bruno
Format: Article
Language:English
Subjects:
Antineoplastic Agents - chemistry
Antineoplastic Agents - pharmacology
Cell Line, Tumor
Cell Proliferation - drug effects
Female
Humans
Hydrocarbons, Aromatic - chemistry
Hydrocarbons, Aromatic - pharmacology
Inhibitory Concentration 50
Models, Molecular
Organometallic Compounds - chemistry
Organometallic Compounds - pharmacology
Ovarian Neoplasms - drug therapy
Ruthenium - chemistry
Ruthenium - pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A series of cationic metalla-cycles of the general formulae [(η(6)-p-cym)(4)Ru(4)(OO∩OO)(2)(N∩N)(2)](4+) and [(η(6)-p-cym)(4)Ru(4)(NO∩NO)(2)(N∩N)(2)](4+) has been prepared from the dinuclear arene ruthenium precursors [(η(6)-p-cym)(2)Ru(2)(OO∩OO)(2)Cl(2)] (OO∩OO = oxalato, 1,4-benzoquinonato-2,5-diolato, 1,4-naphtoquinonato-5,8-diolato, 9,10-anthraquinonato-1,4-diolato, 5,12-tetraquinonato-6,11-diolato) and [(η(6)-p-cym)(2)Ru(2)(NO∩NO)(2)Cl(2)] (NO∩NO = oxamido, oxonico) by reaction with two different bidentate linkers (N∩N = 1,2-bis(4-pyridyl)ethylene, 1,2-bis(4-pyridyl)ethane) in the presence of silver triflate. All complexes were isolated as triflate salts and characterised by NMR, infrared, UV-visible, mass spectrometry and by elemental analysis. The cytotoxicities of the tetranuclear ruthenium complexes have been established using ovarian A2780 and A2780cisR cancer cell lines. All complexes exhibit moderate to excellent activity on both the cisplatin resistant and cisplatin sensitive cells, thus suggesting a mode of action different from cisplatin.
ISSN:1477-9226
1477-9234
DOI:10.1039/c1dt10489f